Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of GDC-9545 in Healthy Females
NCT04274075Phase 1Completed
- Sponsor
- Genentech
- Start
- Mar 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of giredestrant in breast cancer (6 arms), sponsored by Genentech. Primary endpoints: Maximum Observed Plasma Concentration at Day 8, Time to Maximum Observed Plasma Concentration at Day 8 and 3 more. Started Mar 2020; status: completed.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04274075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04274075.